( NYSE:MYOV )

News from Myovant Sciences A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 13, 2017, 16:05 ET Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017

Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for...


Nov 09, 2017, 08:00 ET Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids

Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that...


Oct 16, 2017, 08:45 ET Myovant Sciences Secures Flexible Financing Commitments of up to $140 Million

Myovant Sciences (NYSE: MYOV) today announced that it has secured up to $140 million in flexible financing commitments from NovaQuest Capital...


Oct 02, 2017, 22:19 ET Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids

Myovant Sciences (NYSE: MYOV) today announced that Takeda Pharmaceutical Company Limited ("Takeda") has reported positive top-line results from a...


Aug 10, 2017, 16:30 ET Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017

Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies...


Jul 19, 2017, 16:05 ET Myovant Bolsters Executive Team with Key Management Appointments

Myovant Sciences (NYSE: MYOV) today announced that it has strengthened its executive team through the appointment of four key management...


Jun 29, 2017, 07:00 ET Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Endometriosis-Associated Pain

Myovant Sciences (NYSE: MYOV) today announced it has initiated a Phase 3 clinical program consisting of two international clinical trials, SPIRIT 1...


May 24, 2017, 08:00 ET Myovant Sciences Announces Presentation of Data at the European Congress of Endocrinology from Phase 2 Extension Study Evaluating Relugolix in Women with Endometriosis-Associated Pain

Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a Phase 2 extension study conducted by Takeda Pharmaceutical Company...


May 19, 2017, 16:50 ET Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Endometriosis-Associated Pain at the World Congress on Endometriosis

Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a placebo-controlled Phase 2 study conducted by Takeda Pharmaceutical...


May 18, 2017, 08:00 ET Myovant Sciences Announces Upcoming Presentations of Relugolix Data from Phase 2 Trial in Women with Endometriosis-Associated Pain

Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced...


May 07, 2017, 17:00 ET Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Heavy Menstrual Bleeding and Uterine Fibroids at the Annual Meeting of the American Congress of Obstetricians and Gynecologists

Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a placebo-controlled Phase 2 dose-finding study conducted by...


Mar 01, 2017, 16:45 ET Myovant Sciences Initiates Phase 3 Clinical Trial of Relugolix in Men with Advanced Prostate Cancer

Myovant Sciences (NYSE: MYOV) today announced it has initiated a Phase 3 clinical trial, HERO, to evaluate the safety and efficacy of relugolix in...


Feb 27, 2017, 16:30 ET Myovant Sciences to Present at Upcoming Investor Conferences

Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and other endocrine-related disorders,...


Jan 25, 2017, 07:00 ET Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences (NYSE: MYOV) today announced it has initiated a Phase 3 clinical program consisting of two international clinical trials, LIBERTY...